Articles tagged with “ai-drug-discovery”

Review the 2026 pharma AI vendor landscape. This analysis details 150+ companies using machine learning for drug discovery, clinical trials, and manufacturing.

Analyze Q1 2026 biopharma M&A trends, including 19 billion-dollar deals. Learn how patent cliffs and AI valuation drivers impact pharmaceutical acquisitions.

Analyze the role of multi-agent AI and co-scientist architectures, including withZeta.ai, in accelerating rare cancer drug discovery and modern oncology R&D.

Examine how Isomorphic Labs uses AlphaFold AI to advance its first computationally designed oncology and immunology therapeutics into clinical trials.

An in-depth comparison of AI biology foundation models like AlphaFold 3, ESM3, Boltz-2, and Chai-1. Analyze their architectures, benchmarks, and use cases.

Analyze the Phase IIa clinical trial results of INS018_055 (rentosertib), the first AI-designed drug by Insilico Medicine targeting TNIK for IPF treatment.

An overview of the $1B NVIDIA-Eli Lilly AI lab, detailing its 5-year compute strategy, DGX SuperPOD infrastructure, and foundation models for drug discovery.

Analyze the Chai Discovery and Eli Lilly partnership in AI biologics design. Examine how generative models like Chai-2 impact antibody drug development.

Analyze the Boltz-Pfizer AI drug discovery partnership. This report examines the application of open-source biomolecular foundation models in pharma R&D.

A detailed analysis of the Takeda-Iambic AI drug discovery partnership. Examine the $1.7B deal terms, NeuralPLexer technology, and AI pharma industry trends.

Read an analysis of Amazon Bio Discovery, an AWS agentic AI platform integrating biological foundation models and wet-lab workflows for drug development.

Analyze Insilico Medicine's Pharma.AI platform for AI drug discovery. Learn how PandaOmics, Chemistry42, and MMAI Gym integrate for target and molecule design.

Examine how fine-tuning foundation models and LLMs improves pharmaceutical R&D and drug discovery. Review Insilico's MMAI Gym methodology and AI benchmarks.

Review the $12B wave of Q1 2026 oncology AI deals and pharma M&A. This analysis explains how patent cliffs, CAR-T, and AI drug discovery drive acquisitions.

Analyze how Roche utilizes its NVIDIA AI factory, featuring 3,500 GPUs and Omniverse digital twins, to scale GLP-1 drug manufacturing and optimize pharma R&D.

Analyze the $2.75B partnership between Eli Lilly and Insilico Medicine. Understand how generative AI impacts pharma R&D strategy and drug commercialization.

Analyze Anthropic's $400M acquisition of Coefficient Bio. This report details the integration of large language models and AI in pharmaceutical drug discovery.

Examine how 15 biotech startups utilize artificial intelligence to accelerate pharmaceutical R&D, drug discovery, and clinical trials. Read the full analysis.

Get a detailed list of biotech companies in Toronto (2026). Learn about the life sciences ecosystem, top startups in AI and genomics, and key industry players.

An educational analysis of AI biotech funding in 2025. Explore venture capital investment trends, funding data, and key deals in AI for drug discovery.